PerkinElmer, a biotechnology company, agreed to acquire Oxford Immunotec Global, a medical equipment manufacturing company, for $591m. “Tuberculosis remains one of the leading infectious causes of death, with close to one quarter of the world’s population infected. We believe Oxford Immunotec’s diagnostic testing solution plays an important role in slowing the spread and saving lives. Oxford Immunotec’s highly sensitive test and their team’s passion for solving complex health issues make it a natural fit with PerkinElmer’s mission and together, we believe will accelerate development of robust solutions to help detect infectious disease," Prahlad Singh, PerkinElmer President and CEO.